gatifloxacin has been researched along with Tuberculosis, Meningeal in 2 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Tuberculosis, Meningeal: A form of bacterial meningitis caused by MYCOBACTERIUM TUBERCULOSIS or rarely MYCOBACTERIUM BOVIS. The organism seeds the meninges and forms microtuberculomas which subsequently rupture. The clinical course tends to be subacute, with progressions occurring over a period of several days or longer. Headache and meningeal irritation may be followed by SEIZURES, cranial neuropathies, focal neurologic deficits, somnolence, and eventually COMA. The illness may occur in immunocompetent individuals or as an OPPORTUNISTIC INFECTION in the ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunodeficiency syndromes. (From Adams et al., Principles of Neurology, 6th ed, pp717-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gatifloxacin has a susceptible dose-dependent zone at MICs 0." | 1.48 | Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. ( Ambrose, PG; Bendet, P; Bhavnani, SM; Deshpande, D; Gumbo, T; Gumusboga, M; Koeuth, T; McIlleron, H; Pasipanodya, JG; Smythe, W; Srivastava, S; Thwaites, G; Van Deun, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deshpande, D | 1 |
| Pasipanodya, JG | 1 |
| Srivastava, S | 1 |
| Bendet, P | 1 |
| Koeuth, T | 1 |
| Bhavnani, SM | 2 |
| Ambrose, PG | 2 |
| Smythe, W | 1 |
| McIlleron, H | 1 |
| Thwaites, G | 1 |
| Gumusboga, M | 1 |
| Van Deun, A | 1 |
| Gumbo, T | 1 |
| Thwaites, GE | 1 |
| Chau, TT | 1 |
| Hammel, JP | 1 |
| Török, ME | 1 |
| Van Wart, SA | 1 |
| Mai, PP | 1 |
| Reynolds, DK | 1 |
| Caws, M | 1 |
| Dung, NT | 1 |
| Hien, TT | 1 |
| Kulawy, R | 1 |
| Farrar, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817] | Phase 3 | 520 participants (Actual) | Interventional | 2017-05-25 | Active, not recruiting | ||
| A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786] | Phase 3 | 640 participants (Anticipated) | Interventional | 2018-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for gatifloxacin and Tuberculosis, Meningeal
| Article | Year |
|---|---|
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; | 2011 |
1 other study available for gatifloxacin and Tuberculosis, Meningeal
| Article | Year |
|---|---|
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Lung; Microbial Sensitivity Tests; Monte Carlo Method; | 2018 |